Int. J. Mol. Sci. 2011, 12(9), 5592-5603; doi:10.3390/ijms12095592

Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?

1 Department of Cardiology, Angiology and Pneumology, University of Heidelberg, D-69120 Heidelberg, Germany 2 Faculty of Medicine, University of Heidelberg, D-69120, Heidelberg, Germany
* Author to whom correspondence should be addressed.
Received: 14 July 2011; in revised form: 17 August 2011 / Accepted: 19 August 2011 / Published: 31 August 2011
(This article belongs to the Section Bioactives and Nutraceuticals)
PDF Full-text Download PDF Full-Text [321 KB, uploaded 31 August 2011 13:34 CEST]
Abstract: Epigallocatechin-3-gallate (EGCG), the main and most significant polyphenol in green tea, has shown numerous health promoting effects acting through different pathways, as antioxidant, anti-inflammatory and anti-atherogenic agent, showing gene expression activity, functioning through growth factor-mediated pathways, the mitogen-activated protein kinase-dependent pathway, the ubiquitin/proteasome degradation pathway, as well as eliciting an amyloid protein remodeling activity. However, epidemiological inferences are sometimes conflicting and in vitro and in vivo studies may seem discrepant. Current knowledge on how to enhance bioavailability could be the answer to some of these issues. Furthermore, dose levels, administration frequency and potential side effects remain to be examined.
Keywords: epigallocatechin-3-gallate; green tea; bioavailability

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Mereles, D.; Hunstein, W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int. J. Mol. Sci. 2011, 12, 5592-5603.

AMA Style

Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? International Journal of Molecular Sciences. 2011; 12(9):5592-5603.

Chicago/Turabian Style

Mereles, Derliz; Hunstein, Werner. 2011. "Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?" Int. J. Mol. Sci. 12, no. 9: 5592-5603.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert